Vectibix panitumumab

Drug Class

EGFR antagonist monoclonal antibody

Mechanism

Binds specifically to EGFR, blocking ligand-induced receptor phosphorylation and downstream signaling cascades.

Approved Indication

Wild-type RAS metastatic colorectal cancer as first-line therapy (in combination with FOLFOX) or monotherapy after disease progression, per its FDA approval.

What This Means For Patients

Vectibix is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2006) — Sources

Pivotal Clinical Evidence

• PRIME — Douillard et al., J Clin Oncol 2010 (NCT00371813) — Sources

Sources

• https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-panitumumab-first-line-treatment-patients-wild-type-kras-metastatic-colorectal-cancer
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125147lbl.pdf